[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100602570":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":32,"centralContacts":36,"locations":44,"responsibleParty":62,"collaborators":64,"id":72,"slug":73,"hasResults":74,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":78,"eligibilityCriteria":79,"healthyVolunteers":74,"sex":80,"minAge":81,"maxAge":82,"enrollmentInfo":83,"targetDuration":19,"studyType":86,"phases":87,"briefSummary":89,"conditions":90,"keywords":94,"overallStatus":46,"whyStopped":19,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":107},{"fullName":5,"class":6},"University of California, San Francisco","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"reSTART Intervention","EXPERIMENTAL","The reSTART intervention will be administered to this group and includes: (1) adherence self-monitoring tools delivered during a single baseline motivational interviewing session; (2) the urine tenofovir point-of-care self-test with adherence feedback and visualizations with motivational messages; (3) a positive affect intervention delivered via a mobile health application which supports stimulant-using men in reducing stimulant use.",[13,14],"Behavioral: reSTART Objective Adherence Self-Monitoring and Postive Affect mHealth Intervention","Device: urine tenofovir point-of-care self-test",{"label":16,"type":17,"description":18,"interventionNames":19},"Standard of Care","NO_INTERVENTION","The control group will receive standard of care and will not receive the reSTART intervention.",null,[21,28],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"BEHAVIORAL","reSTART Objective Adherence Self-Monitoring and Postive Affect mHealth Intervention","The reSTART intervention integrates a mobile health application, a urine tenofovir point-of-care self-test, and adherence feedback with motivational messages to increase HIV medication intake, reduce stimulant use, and improve HIV virologic suppression.",[9],[27],"Reactive Driven Support for Treatment, Adherence, Resilience, and Thriving (reSTART)",{"type":29,"name":30,"description":30,"armGroupLabels":31,"otherNames":19},"DEVICE","urine tenofovir point-of-care self-test",[9],[33],{"name":34,"affiliation":5,"role":35},"Matthew Spinelli, MD, MAS","PRINCIPAL_INVESTIGATOR",[37,42],{"name":38,"role":39,"phone":40,"phoneExt":19,"email":41},"Shivani Mahuvakar","CONTACT","415-878-6384","shivani.mahuvakar@ucsf.edu",{"name":43,"role":39,"phone":19,"phoneExt":19,"email":19},"Kevin Sassaman",[45],{"facility":5,"status":46,"city":47,"state":48,"zip":49,"country":50,"countryCode":51,"cosmosGeoPoint":52,"geoPoint":57,"contacts":58},"RECRUITING","San Francisco","California","94110","United States","US",{"type":53,"coordinates":54},"Point",[55,56],-122.41942,37.77493,{"lat":56,"lon":55},[59],{"name":34,"role":39,"phone":60,"phoneExt":19,"email":61},"415-806-8554","matthew.spinelli@ucsf.edu",{"type":63,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR",[65,67,69],{"name":66,"class":6},"Florida International University",{"name":68,"class":6},"San Diego State University",{"name":70,"class":71},"National Institute on Drug Abuse (NIDA)","NIH","100602570","reactive-driven-support-for-treatment-adherence-resilience-and-thriving-restart-clinical-trial-100602570",false,"NCT07125235","Reactive Driven Support for Treatment, Adherence, Resilience, and Thriving (reSTART) Clinical Trial","Reactive Driven Support for Treatment, Adherence, Resilience, and Thriving (reSTART) mHealth Randomized Controlled Hybrid Type I Effectiveness Implementation Trial","reSTART","Inclusion Criteria:\n\n* Prescribed antiretroviral therapy (ART) with a tenofovir-based regimen.\n* Documented virologic non-suppression, urine tenofovir testing without tenofovir detected, or self-reported adherence \\\u003C100%.\n* Reports stimulant use.\n* Has a mailing address within the U.S.\n* Currently has a smartphone with photo capabilities.\n\nExclusion Criteria:\n\n* Have any health condition that may interfere with participation or the ability to provide informed consent, including any debilitating or life-threatening conditions.\n* Not prescribed ART.\n* Unwilling to perform urine self-testing or to attend a local Quest site for viral load monitoring.\n* Unable to provide a hair sample of \\~50-100 strands of hair that are non-gray, not bleached, and at least 1cm in length","MALE","18 Years","70 Years",{"count":84,"type":85},270,"ESTIMATED","INTERVENTIONAL",[88],"NA","Men who are living with HIV and use stimulants face many challenges and barriers that may interfere with remembering to take their HIV medication. Forgetting to take HIV medication puts men living with HIV at a greater risk of becoming virally unsuppressed. Researchers are doing this study to test if a remote intervention can help participants improve remembering to take their HIV medications and reduce the HIV viral load among men living with HIV who use stimulants.",[91,92,93],"Behavioral Intervention","Viral Suppression of HIV Infection","ART Adherence",[95,96,97],"HIV","Stimulant Use","mHealth","2026-03-11",{"date":100,"type":101},"2026-03-13","ACTUAL",{"date":103,"type":101},"2026-02-09",{"date":105,"type":85},"2028-07-30",{"name":5,"class":6},1]